Deltex Medical Group plc announced the UK and EU launch of its new next generation TrueVue System. The launch follows the successful independent review of the electromagnetic compatibility (EMC) report on the new TrueVue monitor as well as the subsequent finalisation of the technical file, as referred to in the Group's announcement on 6 July 2023. With the new next generation TrueVue system now CE marked and released in the UK and EU, the Group is now able to deploy the device for in-hospital evaluations, to ensure that there are no teething issues with the launch, and will not fulfil any orders until this is completed.

It is anticipated that this will take approximately 3 months and therefore the Group is forecasting revenue from new monitor sales to commence in November 2023. This is normal practice for any medical device, as it is not permitted to use a device in a hospital unless it has been CE marked. The new TrueVue System combines independent measurements of blood flow and blood pressure in a patient across each and every heartbeat in real time, providing the clinician with a range of clinically validated haemodynamic parameters.

These haemodynamic parameters are used by clinicians to assess the patient's cardiac function to guide fluid and drug therapy to optimise cardiovascular performance (heart contractility) or normalise circulating blood volume (normovolaemia). The new next generation TrueVueSystem is a major advance over Deltex Medical's existing system. The light-weight p ortable multi-technology device is battery powered and has a significantly easier user interface.

The technology is expected to be used in adult and paediatric patients undergoing surgery (including in Accident and Emergency (A&E)) or during treatment in critical care departments such as Intensive Care Units (ICU) or High Dependency Units (HDU). The new next generation True Vue System will also be the platform for the Group's new non-invasive Suprasternal device, which is currently under development.